• Nano Today Conference
  • Symposium on Science

A*STAR Outstanding Publications Award
2009, 2010, 2012, 2013, 2014, 2016 and 2017
A*STAR Patent Power Award
2009, 2010 and 2017
Singapore HEALTH Award
(Platinum) 2012, (Gold) 2008 and 2010
BCA Green Mark Award
2013 (Gold) and 2017 (Gold and Goldplus)

RESEARCH AREAS > Research Staff Details

Synthetic Biosystems

   

YU Hanry
Group Leader

Tel: 6824 7103
Email: hyu@ibn.a-star.edu.sg

View CV

Visiting Professor, Department of Biological Engineering, Massachusetts Institute of Technology (MIT), USA, 2011-2013
Principal Investigator, MechanoBiology Institute, Singapore, since 2011
Director, NUHS Research Core Facilities, Confocal Microscopy Unit & Flow Cytometry
Laboratory, National University Health System, since 2011
Professor, Department of Physiology, Faculty of Medicine, National University of Singapore, since 2008

Ph. D. in Cell Biology, Duke University, 1994
M. Sc. in Biochemistry and Molecular Biology, Washington University-St. Louis, 1990
B. Sc. (Hons.) in Biochemistry, Michigan State University, 1987

Projects Publications Patents

Synthetic Biosystems

1. Digital Livers: Quantitative Analysis of the Dynamic Processes of Liver Regeneration and Chronic Liver Diseases

Ziwei Song, Yu Yang and Hanry Yu

We have developed optical imaging modalities to quantify cellular and extracellular changes in tissues. The instruments and machine-learning based image-processing/feature analysis algorithms developed are used to automate and improve pathological examinations related to (i) liver fibrosis, (ii) cholestasis and (iii) non-alcoholic fatty liver diseases. This helps to shed light on the etiology of the diseases quantitatively. We have developed a high-throughput tissue imaging platform to quantify tissue/cell and matrix features of big blocks of tissue in mice or the entire biopsy sample at molecular and cellular resolutions for 3D characterization of disease progression. We have spun off an award-winning company, HistoIndex Pte Ltd, from this project, and licensed key technologies to another start-up company, InvitroCue Pte Ltd, to create an impact in the digital pathology and telemedicine landscape. The team is also investigating the fundamental process of liver regeneration by quantifying and modeling the mechanical and biochemical regulation of the cellular hypertrophy.

2. Drug Testing Platforms: Development of Robust, Inexpensive, Scalable and Predictive Assays for Safety Testing of Drugs and Chemicals

Farah Tasnim, Jiangwa Xing, Xiaozhong Huang and Hanry Yu

Cell-based assays for in vitro toxicity evaluation are attracting increasing attention from institutions and companies involved in the development of drugs and industrial chemicals. The major bottlenecks are the lack of stable human primary cells, and cell-culture models that recapitulate the in vivo physiological responses to the tested compounds. So far, only the sandwich culture of liver cells is accepted by the Federal Drug Administration (FDA) for routine hepatotoxicity testing of drugs. To improve the cell-based assays, we have developed (i) a scalable aligned substrate on optical media, (ii) two improved spheroid models for acute and chronic toxicity testing, respectively, (iii) a co-culture model for idiosyncratic toxicity, (iv) three perfusion-based models for improved sensitivity to detect metabolites, (v) a developmental toxin based on morphogenic migration of human stem cells, and (vi) stable and robust cell sources from human stem or progenitor cells. We are validating these established models for hepatotoxicity and teratogen testing of compounds, and improving the performance of these platforms for robustness, predictive fidelity, scalability and cost. We are also extending the applications of these models to sub-acute/chronic hepatotoxicity in order to better mimic “in vivo-like” conditions.

3. Engineering Complex Tissues: Spatial and Temporal Control of Microenvironment

Zheng Liu (Justinian), Farah Tasnim and Hanry Yu

Complex tissues with multiple cell types will be engineered by controlling cell-cell and cell-matrix interactions through (i) engineering inter-cellular linkers for 3D printing, (ii) engineering cellular response to the chemical and mechanical signals by developing ultra-soft macroporous sponges that are robust, transparent, degradable and enhancing compact spheroid formation, and (iii) fabricating relevant 3D microfluidics, micro-patterns and ultra-thin porous membranes incorporating mechanical compaction and multiple cell types for organ-on-a-chip applications, such as a liver cancer chip to aid chemotherapy testing. This project establishes the fundamental principles, toolboxes and devices to precision-engineer micro-tissue constructs of different cell types and inter-cellular tissue space (such as sinusoid and bile canaliculi in liver) for repeated dose testing of compounds that require mid-term (> 2-4 weeks) or long-term (up to 6 weeks) culture of micro-tissue constructs.

EVENTS

2017
15 Nov
Symposium on Science: Frontiers in Biology

6 Dec - 10 Dec
5th Nano Today Conference

Event Calendar   

One-North Run 2017

FEATURED PUBLICATIONS

NEW! Genetic Alphabet Expansion Biotechnology by Creating Unnatural Base Pairs
Current Opinion in Biotechnology, 51 (2018) 8-15.
(IF: 9.294) article

NEW! Remanence Plots as a Probe of Spin Disorder in Magnetic Nanoparticles
Chemistry of Materials, (2017)
DOI: 10.1021/acs.chemmater.7b02522.
(IF: 9.466) article

NEW! Hyaluronic Acid-Green Tea Catechin Micellar Nanocomplex: Fail-Safe Cisplatin Nanomedicine for the Treatment of Ovarian Cancer Without Off-Target Toxicity
Biomaterials, (2017)
DOI: 10.1016/j.biomaterials.2017.09.027.
(IF: 8.402) article

More   

JOIN US!

Research Positions

Corporate Administration Positions

Institute of Bioengineering and Nanotechnology   31 Biopolis Way, The Nanos, #04-01, Singapore 138669   Tel: +65 6824 7000   Fax: +65 6478 9080   Email: enquiry@ibn.a-star.edu.sg   |   View IBN Privacy Statement